ES2074563T3 - Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico. - Google Patents

Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.

Info

Publication number
ES2074563T3
ES2074563T3 ES90902432T ES90902432T ES2074563T3 ES 2074563 T3 ES2074563 T3 ES 2074563T3 ES 90902432 T ES90902432 T ES 90902432T ES 90902432 T ES90902432 T ES 90902432T ES 2074563 T3 ES2074563 T3 ES 2074563T3
Authority
ES
Spain
Prior art keywords
treatment
gram
septic shock
negative bacteria
septicemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902432T
Other languages
English (en)
Inventor
Joyce E Lawrence
Michael J Griffith
Melaine Alpern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23160797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074563(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2074563T3 publication Critical patent/ES2074563T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS USADAS PARA EL TRATAMIENTO O PROFILAXIS DE ATAQUES DE BACTERIAS GRAM-NEGATIVAS O DE CHOQUES SEPTICOS, QUE CONTIENEN UNA CANTIDAD SUFICIENTE ANTIBACTERIANA DE INMUNOGLOBULINAS POLICLONICAS CONTRA BACTERIAS GRAM-NEGATIVAS Y UNA CANTIDAD EFECTIVA DE PROTEINA C PARA DISOLVER COAGULOS EN LA SANGRE. LAS COMPOSICIONES PUEDEN CONTENER ADEMAS UNO O MAS COFACTORES DE PROTEINA C Y ANTICUERPOS MONOCLONICOS CONTRA ENDOTOXINAS DE BACTERIAS GRAM-NEGATIVAS. UN METODO PARA EL TRATAMIENTO O PROFILAXIS DE INFECCIONES BACTERIANAS GRAM-NEGATIVAS, O DE CHOQUES SEPTICOS, COMPRENDE LA ADMINISTRACION, JUNTOS O POR SEPARADO, DE UNA CANTIDAD ANTIBACTERIANA EFECTIVA DE INMUNOGLOBULINAS POLICLONICAS CONTRA BACTERIAS GRAM-NEGATIVAS Y DE UNA CANTIDAD EFECTIVA DE PROTEINA C PARA DISOLVER COAGULOS SANGUINEOS. EL METODO PUEDE INCLUIR OPCIONALMENTE ADMINISTRAR UNO O MAS COFACTORES DE PROTEINA C Y ANTICUERPOS MONOCLONICOS CONTRA ENDOTOXINAS DE BACTERIAS GRAM-NEGATIVAS.
ES90902432T 1989-01-24 1990-01-17 Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico. Expired - Lifetime ES2074563T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/300,836 US5093117A (en) 1989-01-24 1989-01-24 Compositions and method for the treatment or prophylaxis of sepsis or septic shock

Publications (1)

Publication Number Publication Date
ES2074563T3 true ES2074563T3 (es) 1995-09-16

Family

ID=23160797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902432T Expired - Lifetime ES2074563T3 (es) 1989-01-24 1990-01-17 Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.

Country Status (8)

Country Link
US (1) US5093117A (es)
EP (1) EP0406398B1 (es)
JP (1) JP3038006B2 (es)
CA (1) CA1339990C (es)
DE (1) DE69019072T2 (es)
DK (1) DK0406398T3 (es)
ES (1) ES2074563T3 (es)
WO (1) WO1990008556A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1994002172A1 (en) 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
DE69434332T2 (de) * 1993-11-12 2006-02-02 Gilead Sciences, Inc., Foster City Thrombin mutanten
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
US6159468A (en) * 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
DE19726248C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Behandlung von septischem Schock
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
US6679870B1 (en) 1999-07-23 2004-01-20 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6685694B2 (en) 1999-07-23 2004-02-03 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
CA2437099A1 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
EP1357943A2 (en) * 2001-01-30 2003-11-05 The Lauridsen Group Incorporated Methods and compositions for modulating the immune system of animals
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
ES2387275T3 (es) 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
ITFI20070063A1 (it) * 2007-03-15 2008-09-16 Kedrion Spa Concentrato di proteina c contenente proteina s, sua preparazione ed uso.
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
DE3516119A1 (de) * 1985-05-04 1986-11-06 Biotest Pharma GmbH, 6000 Frankfurt Polyvalentes hyperimmunglobulin-praeparat
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S

Also Published As

Publication number Publication date
EP0406398A1 (en) 1991-01-09
US5093117A (en) 1992-03-03
CA1339990C (en) 1998-08-11
JP3038006B2 (ja) 2000-05-08
WO1990008556A1 (en) 1990-08-09
JPH03503536A (ja) 1991-08-08
EP0406398B1 (en) 1995-05-03
DE69019072D1 (de) 1995-06-08
EP0406398A4 (en) 1991-07-03
DK0406398T3 (da) 1995-07-17
DE69019072T2 (de) 1995-11-30

Similar Documents

Publication Publication Date Title
ES2074563T3 (es) Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
ES2178656T3 (es) Metodo para tratar infeccion bacteriana gram-negativa por administracion de productos de proteina bactericida que aumenta la permebilidad(bpi) y antibioticos.
TR199903053T2 (xx) Benzimidazol t�revleri.
ATE25245T1 (de) Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel.
DK84083D0 (da) Fremgangsmade til fremstilling af polysaccharid-protein-komplekser ud fra bakterielle kapsler
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
NO884391D0 (no) Legemiddel-lipidsystemer med lav toksisitet.
PT90592A (pt) Processo para a preparacao do antibiotico galidermina e de composicoes farmaceuticas e cosmeticas que o contem
BR9406059A (pt) Composição farmacéutica e método para tratamento de uma infecção helmintica em um animal
DK0737072T3 (da) Anvendelse af simple og konjugerede dekstraner ved fremstilling af et medikament til at forhindre eller nedsætte risikoen f
AR023645A1 (es) Metodo para tratar una infeccion por estafilococos
DK577181A (da) Polypeptidfraktioner fra muslinger
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
SE8605044L (sv) Komposition for utvertes bruk
BR9911944A (pt) Proteìna inibidora da quimiotaxia do staphylococcus (proteìna chips) e sua utilização
NO945031D0 (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
ES508985A0 (es) Procedimiento microbiologico para la obtencion de un nuevo compuesto antibiotico de la cepa streptomyces.
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
FI884041A (fi) Desinfiointikoostumus stafylokokkien tappamiseksi
DK1458390T3 (da) Fremgangsmåde til behandling af bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et carbapenem antibakterielt middel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 406398

Country of ref document: ES